Tinnitus Hearing
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: Aged 18 years or older; both genders; present a pure-tone average = 50 dB HL; and report constant tinnitus for at least six months; Individuals currently using ototoxic medication will be excluded from the study
Exclusion criteria
Exclusion criteria: Participants will be excluded if they present neurological or cognitive impairments that prevent adequate understanding of the study procedures; a history of acute or chronic otologic disorders; tympanic membrane perforation or otorrhea; history of meningitis; conductive or mixed hearing loss; somatosensory tinnitus influenced by temporomandibular disorders (TMD); or if they have undergone any specific tinnitus treatment within the month prior to study enrollment. Individuals presenting any contraindication to photobiomodulation therapy will also be excluded, including tumors or neoplasms, pacemakers or other electronic implants, pregnancy, use of retinoic acid or vitamin A derivatives (retinoic acid, retinol A, tretinoin, isotretinoin), antibiotic therapy with tetracycline, history of photosensitivity, use of anticoagulant medication, or history of thrombosis
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary outcome will be tinnitus-related handicap measured by the Tinnitus Handicap Inventory (THI). Assessments will be conducted at baseline (prior to intervention), immediately after the final intervention session, and 15 days after the completion of treatment. | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary outcomes will include tinnitus intensity measured by acuphenometry and tinnitus-related discomfort measured using the Visual Analog Scale (VAS). These measures will be assessed at baseline (prior to intervention), immediately after the final intervention session, and 15 days after the completion of treatment. | — |
Countries
BR
Contacts
Universidade do Estado da Bahia